Anti-PD 1 Drug Extends PFS in Stage III NSCLC (CME/CE)

(MedPage Today) -- Progression-free survival three times longer with durvalumab after chemoradiation
Source: MedPage Today State Required CME - Category: Consumer Health News Source Type: news